Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gpi-1485 SCHEMBL3568704 | 1.00 | FKBP1A (0.66) | FKBP1ALMNACYP2C19HSD17B10 | |
| SCHEMBL499064 | 0.95 | FKBP1A (0.72) | FKBP1A | |
| SCHEMBL5966171 | 0.95 | FKBP1A (0.72) | FKBP1A | |
| SCHEMBL4675555 | 0.95 | FKBP1A (0.72) | FKBP1A | |
| SCHEMBL6317432 | 0.90 | FKBP1A (0.57) | FKBP1A | |
| Trifluoroacetic Acid SCHEMBL499188 | 0.89 | FKBP1A (0.64) | FKBP1A | |
| SCHEMBL4675854 | 0.88 | FKBP1A (0.63) | FKBP1A | |
| SCHEMBL5275878 | 0.88 | FKBP1A (0.63) | FKBP1A | |
| SCHEMBL3330557 | 0.88 | LMNA (0.57) | FKBP1ALMNACYP2C19HSD17B10 | |
| SCHEMBL10034614 | 0.88 | FKBP1A (0.66) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4118431-B1 | INHIBITION OF FKBP1A FOR THE TREATMENT OF TRIPLE-NEGATIVE MAMMARY CARCINOMA | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4274570-B1 | ACTIVATORS OF THE BMP/SMAD AXIS FOR USE IN TREATING AND/OR PREVENTING MUSCLE ATROPHY | UNIV DEGLI STUDI DI TORINO (IT) | 2025-12-24 | — | — | EP | claimed |
| US-20240269125-A1 | METHODS OF TREATING CORONAVIRUS INFECTIONS BY CO-ADMINISTERING AN FKBP LIGAND AND AN ANTIVIRAL AGENT | TUTELA PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | claimed |
| US-20240245787-A1 | E3 LIGASE BINDERS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-25 | — | — | US | claimed |
| EP-4323340-A2 | E3 LIGASE BINDERS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-02-21 | — | — | EP | claimed |
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | YALE UNIVERSITY | 2023-05-25 | — | — | US | claimed |
| EP-4118431-A1 | INHIBITION OF FKBP1A FOR THE TREATMENT OF TRIPLE-NEGATIVE MAMMARY CARCINOMA | Heinrich-Heine-Universität Düsseldorf (DE) | 2023-01-18 | — | — | EP | claimed |
| WO-2022221413-A2 | E3 LIGASE BINDERS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-20 | — | — | WO | claimed |
| WO-2022035911-A2 | METHODS OF TREATING CORONAVIRUS INFECTIONS BY CO-ADMINISTERING AN FKBP LIGAND AND AN ANTIVIRAL AGENT | TUTELA PHARMACEUTICALS, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| US-7960570-B2 | Small molecule inhibitors of rotamase enzyme activity | GLIAMED, INC. (US) | 2011-06-14 | — | — | US | claimed |
| WO-2000017161-A1 | CYCLIC ESTER OR AMIDE DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| WO-2000009124-A1 | PYRROLIDINE DERIVATIVES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | claimed |
| US-5859031-A | Small molecule inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998055091-A1 | PYRROLIDINE DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-10 | — | — | WO | claimed |
| EP-0769006-A4 | — | GUILFORD PHARM INC (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0769006-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1997-04-23 | — | — | EP | claimed |
| US-5614547-A | Small molecule inhibitors of rotamase enzyme | GUILFORD PHARMACEUTICALS INC. (US) | 1997-03-25 | — | — | US | claimed |
| WO-1996040633-A9 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | — | 1997-02-27 | — | — | WO | claimed |
| WO-1996040633-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | CD47, CD4, CD2 | FKBP1A 4298/4885LMNA 4695/4885CYP2C19 4877/4885 |
| US-20240245787-A1 | E3 LIGASE BINDERS AND USES THEREOF | XIAP, UBE3A, UBE3C | FKBP1A 869/4885LMNA 1119/4885CYP2C19 4516/4885 |
| US-20240269125-A1 | METHODS OF TREATING CORONAVIRUS INFECTIONS BY CO-ADMINISTERING AN FKBP LIGAND AND AN ANTIVIRAL AGENT | SARS1, FKBP1A, FKBP8 | FKBP1A 2/4885LMNA 4036/4885CYP2C19 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.